173 related articles for article (PubMed ID: 19324411)
1. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes.
Wang R; Gross CP; Halene S; Ma X
Leuk Res; 2009 Dec; 33(12):1594-8. PubMed ID: 19324411
[TBL] [Abstract][Full Text] [Related]
2. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.
Rozema J; Hoogendoorn M; Kibbelaar R; van den Berg E; Veeger N; van Roon E
Blood Adv; 2021 Mar; 5(5):1344-1351. PubMed ID: 33656535
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Strupp C; Ambaglio I; Kuendgen A; Zipperer E; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Mar; 96(3):441-9. PubMed ID: 21134982
[TBL] [Abstract][Full Text] [Related]
4. The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.
Castelli R; Schiavon R; Deliliers GL
Med Oncol; 2018 Feb; 35(3):33. PubMed ID: 29417235
[TBL] [Abstract][Full Text] [Related]
5. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.
Fega KR; Abel GA; Motyckova G; Sherman AE; DeAngelo DJ; Steensma DP; Galinsky I; Wadleigh M; Stone RM; Driver JA
J Geriatr Oncol; 2015 Jul; 6(4):288-98. PubMed ID: 26073533
[TBL] [Abstract][Full Text] [Related]
6. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Naqvi K; Garcia-Manero G; Sardesai S; Oh J; Vigil CE; Pierce S; Lei X; Shan J; Kantarjian HM; Suarez-Almazor ME
J Clin Oncol; 2011 Jun; 29(16):2240-6. PubMed ID: 21537048
[TBL] [Abstract][Full Text] [Related]
7. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes.
Ma X; Wang R; Galili N; Mayne ST; Wang SA; Yu H; Raza A
Cancer Causes Control; 2011 Apr; 22(4):623-9. PubMed ID: 21287258
[TBL] [Abstract][Full Text] [Related]
8. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
9. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Buckstein R; Wells RA; Zhu N; Leitch HA; Nevill TJ; Yee KW; Leber B; Sabloff M; St Hilaire E; Kumar R; Geddes M; Shamy A; Storring J; Kew A; Elemary M; Levitt M; Lenis M; Mamedov A; Zhang L; Rockwood K; Alibhai SM
Br J Haematol; 2016 Jul; 174(1):88-101. PubMed ID: 26991631
[TBL] [Abstract][Full Text] [Related]
10. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
11. The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.
Falantes JF; Márquez-Malaver FJ; Knight T; Calderón-Cabrera C; Martino ML; González J; Montero I; Espigado I; Pérez-Simón JA
Leuk Lymphoma; 2017 Aug; 58(8):1893-1902. PubMed ID: 27951729
[TBL] [Abstract][Full Text] [Related]
12. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
Efficace F; Gaidano G; Breccia M; Voso MT; Cottone F; Angelucci E; Caocci G; Stauder R; Selleslag D; Sprangers M; Platzbecker U; Ricco A; Sanpaolo G; Beyne-Rauzy O; Buccisano F; Palumbo GA; Bowen D; Nguyen K; Niscola P; Vignetti M; Mandelli F
Lancet Oncol; 2015 Nov; 16(15):1506-1514. PubMed ID: 26404501
[TBL] [Abstract][Full Text] [Related]
14. MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients.
Larfors G; Moreno Berggren D; Garelius H; Nilsson L; Rasmussen B; Hellström-Lindberg E; Ejerblad E
Leuk Res; 2023 Nov; 134():107386. PubMed ID: 37690322
[TBL] [Abstract][Full Text] [Related]
15. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
17. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis.
Adrianzen-Herrera D; Sparks AD; Singh R; Alejos-Castillo D; Batra A; Glushakow-Smith S; Pradhan K; Shastri A; Zakai NA
Blood Adv; 2023 Nov; 7(22):6913-6922. PubMed ID: 37729616
[TBL] [Abstract][Full Text] [Related]
18. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.
Zeidan AM; Wang R; Davidoff AJ; Ma S; Zhao Y; Gore SD; Gross CP; Ma X
Cancer; 2016 May; 122(10):1598-607. PubMed ID: 26970288
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
[TBL] [Abstract][Full Text] [Related]
20. The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis.
Yang Y; Tang Z; An T; Zhao L
Medicine (Baltimore); 2019 Oct; 98(40):e17406. PubMed ID: 31577751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]